课题基金 / 基金详情

Study on HDL metabolism and atherogenesity in type 2 diabetics with Taq IBB2B2 polymorphism

Study on HDL metabolism and atherogenesity in type 2 diabetics with Taq IBB2B2 polymorphism
Taq IBB2B2多态性2型糖尿病HDL代谢及动脉粥样硬化研究
批准号:
14571113
负责人:
MURAKAMI Toru
金额:
$0.64万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

MURAKAMI Toru的其他基金

相关文献

中文摘要
翻译
研究单纯饮食控制的2型糖尿病患者血清高密度脂蛋白胆固醇水平与taqi基因多态性的关系。对象60例:B1B1 20例,B1B2 20例,B2B2各20例。B2B2基因多态性与血清高密度脂蛋白胆固醇水平升高密切相关。糖尿病患者血浆中逆向胆固醇系统主要受损。因此,该结果是否显示对动脉粥样硬化有抑制作用尚不清楚。我们的结果表明,糖尿病患者的胆固醇酯转移率比非糖尿病患者降低了20%。B2基因多态性与血清高密度脂蛋白胆固醇浓度升高有关,但从人血浆胆固醇逆向转运系统的角度来看,可能不正常。未来,我们必须研究影响血清HDL胆固醇浓度和HDL功能的遗传背景。本文研究了taqib基因多态性与60例糖尿病患者冠状动脉狭窄的关系,其中B1B1 20例,B1B2 20例,B2B2 20例,B2B2 20例相互匹配,符合年龄、性别和血脂。对象60例:B1B1 20例,B1B2 20例,B2B2各20例。没有证据表明冠状动脉狭窄与taqi多态性和血清高密度脂蛋白胆固醇浓度降低有关。也许基因与基因的相互作用在这方面起着重要的作用。
英文摘要
We evaluated the relation between serum HDL cholesterol level and Taq I gene polymorphism in patients with type 2 diabetes mellitus controlled with diet alone. Subjects were 60: B1B1 20 cases, B1B2 20, B2B2 20 each other. B2B2 gene polymorphism was closely related with higher serum HDL cholesterol level. In diabetes, reverse cholesterol system is essentially impaired in plasma. Therefore, if this result shows an inhibitory effect to atherosclerosis is unclear. Our result indicated that cholesteryl ester transfer rate showed 20 % decreased in patients of diabetes mellitus compared with non diabetes. B2 gene polymorphism was contributed to increase serum HDL cholesterol concentration but may not act normal from the view point of reverse cholesterol transport system in human plasma. In future, we must examine the genetic background affecting serum HDL cholesterol concentration and HDL function.We now examine the relation between Taq I B gene polymorphism and Subjects were 60: B1B1 20 cases, B1B2 20, B2B2 20 each other coronary stenosis in patients with diabetes mellitus which were matched age-, sex-, and serum lipid. Subjects were 60: B1B1 20 cases, B1B2 20, B2B2 20 each other. There are no evidence that coronary stenosis is related with Taq I polymorphism and decreased serum HDL cholesterol concentration. May be gene-gene interaction may pray an important role in this respect.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
村上透: "スタチン系薬剤の多面的効果と安全性"名古屋内科医会会誌. 111. 39-50 (2002)
村上彻:“他汀类药物的多方面作用和安全性”名古屋医学会杂志 111. 39-50 (2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
松原千明, 村上 透 他: "LPL遺伝子イントロン6変異領域C alleleは非肥満における高トリグリセリド血症の遺伝的要因である"肥満研究. 19(1). 78-79 (2003)
Chiaki Matsubara、Toru Murakami 等:“LPL 基因内含子 6 突变区 C 等位基因是非肥胖患者高甘油三酯血症的遗传因素”Obesity Research 19(1) (2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kageyama H, Murakami T, et al.: "Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma"Biochem Biophys Res Commun. 23:305(1). 22-27 (2003)
Kageyama H、Murakami T 等人:“吡格列酮通过 PPAR-γ 增加了白色脂肪组织中的脂蛋白脂肪酶 mRNA,但骨骼肌中则没有”Biochem Biophys Res Commun。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kageyama, H., Hirano, T., Okada, K., Ebara, T., kageyama, A., Murakami, T.Shioda, S., Adachi, M.: "Lipoprotein lipase mRNA in white adipose tissu but not in skeletal muscle is increased by pioglitazone through PPAR-gamma."Biochem Biophys Res commun. 23;30
Kageyama, H.、Hirano, T.、Okada, K.、Ebara, T.、kageyama, A.、Murakami, T.Shioda, S.、Adachi, M.:“白色脂肪组织中有脂蛋白脂肪酶 mRNA,但在白色脂肪组织中没有
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 10 条
    Study on plasma HDL-C concentration and HDL remodeling in CETP genc polymorphism
    • 批准号:
      12671129
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $0.7万
    • 财政年份:
      2000
    • 负责人:
      MURAKAMI Toru
    • 依托单位: